What is SUMATRIPTAN SUCCINATE used for?

SUMATRIPTAN SUCCINATE (brand name SUMATRIPTAN SUCCINATE) is a Triptan (Migraine) indicated for 1 INDICATIONS AND USAGE Sumatriptan injection is indicated in adults for (1) the acute treatment of migraine, with or without aura.

What are the most common side effects of SUMATRIPTAN SUCCINATE?

Reported side effects vary by individual. The side-effects section on this page lists the events most frequently reported to FDA FAERS for SUMATRIPTAN SUCCINATE. FAERS is voluntary reporting, so it reflects what was reported, not absolute incidence.

Is SUMATRIPTAN SUCCINATE the same as SUMATRIPTAN SUCCINATE?

SUMATRIPTAN SUCCINATE is a brand name for SUMATRIPTAN SUCCINATE. They share the same active ingredient and FDA-approved indications. Biosimilars and authorised generics may differ in inactive ingredients such as buffers or preservatives.

SUMATRIPTAN SUCCINATE

Q: How does SUMATRIPTAN SUCCINATE work?

SUMATRIPTAN SUCCINATE works through the following mechanism: 12.1 Mechanism of Action Sumatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine and cluster headaches through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release..

Triptan (Migraine)

Brand names: SUMATRIPTAN SUCCINATE, Treximet

Subcutaneous

Mechanism of Action

12.1 Mechanism of Action Sumatriptan binds with high affinity to human cloned 5-HT 1B/1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine and cluster headaches through agonist effects at the 5-HT 1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.

Indications

1 INDICATIONS AND USAGE Sumatriptan injection is indicated in adults for (1) the acute treatment of migraine

with or without aura

Contraindications

• 4 CONTRAINDICATIONS Sumatriptan injection is contraindicated in patients with: Ischemic coronary artery disease (CAD) (angina pectoris
• history of myocardial infarction
• or documented silent ischemia) or coronary artery vasospasm
• within 24 hours) of ergotamine-containing medication
• ergot-type medication (such as dihydroergotamine or methysergide)

FDA Warnings

5 WARNINGS AND PRECAUTIONS Myocardial ischemia/infarction and Prinzmetal’s angina: Perform cardiac evaluation in patients with multiple cardiovascular risk factors
2 ) Chest/throat/neck/jaw pain, tightness, pressure, or heaviness: Generally not associated with myocardial ischemia; evaluate for coronary artery disease in patients at high risk
1 Myocardial Ischemia, Myocardial Infarction, and Prinzmetal’s Angina The use of sumatriptan injection is contraindicated in patients with ischemic or vasospastic CAD
There have been rare reports of serious cardiac adverse reactions, including acute myocardial infarction, occurring within a few hours following administration of sumatriptan injection

Known Side Effects

12 documented side effects by frequency

Drug Not Working

>10%

Headache

>10%

Nausea

1-10%

Fatigue

1-10%

Dizziness

1-10%

Vomiting

1-10%

Shortness of Breath

0.1-1%

Anxiety

0.1-1%

Diarrhea

0.1-1%

General Unwellness

0.1-1%

Joint Pain

0.1-1%

Depression

0.1-1%

Community Discussions

No community discussions found for SUMATRIPTAN SUCCINATE yet.

Primary sources

Every figure on this page links back to its primary source. See data sources for full provenance.

DailyMed FDA label search → SUMATRIPTAN SUCCINATE openFDA label JSON → SUMATRIPTAN SUCCINATE FAERS adverse-event reports → SUMATRIPTAN SUCCINATE ClinicalTrials.gov → completed Phase 2+ trials of SUMATRIPTAN SUCCINATE

Compare With

10 available comparisons

Formulations

Dosage Forms

Tablet

Route

Subcutaneous